Palliative chemotherapy for advanced gastric cancer. - Wikidata - awgldk - TriplyDB

Palliative chemotherapy for advanced gastric cancer.

Palliative chemotherapy for advanced gastric cancer.

http://www.wikidata.org/entity/Q35936039

about

The use of lentinan for treating gastric cancer Comparison of Prognostic MicroRNA Biomarkers in Blood and Tissues for Gastric Cancer Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis Hepatoid adenocarcinoma of the stomach – a different histology for not so different gastric adenocarcinoma: a case report Molecular mechanisms of chemoresistance in gastric cancer Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.Identification of prognostic factors and surgical indications for metastatic gastric cancer.Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.Inhibition of p600 expression suppresses both invasiveness and anoikis resistance of gastric cancer.Chemotherapy for advanced gastric cancer: across the years for a standard of care.Association among polymorphisms in EGFR gene exons, lifestyle and risk of gastric cancer with gender differences in Chinese Han subjects.Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.Quality of life in patients with oesophageal and gastric cancer: an overview.Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports.Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers Upper gastrointestinal tumors: current status and future perspectives.Oncogenic pathway combinations predict clinical prognosis in gastric cancer.Emerging role of capecitabine in gastric cancer.Long non-coding RNA CCAT2 promotes gastric cancer proliferation and invasion by regulating the E-cadherin and LATS2.Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer.Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.Dysregulation of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901.Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer.Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study.Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of Hospital Episode Statistics.Gastric Hepatoid Carcinoma Presenting Initially as GIST on CT Scan.Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.Methylation subtypes and large-scale epigenetic alterations in gastric cancer.

P2860

Q24619416-6E369592-DB32-4B11-9557-298EA61BD645 Q26771422-0C393EFD-A5DF-4080-97E8-00E94C0EE09D Q26824719-0558093B-FECF-471B-9F52-544977BB1C13 Q27002415-2FA3269A-72B8-494F-9F52-D7298F458A45 Q27497441-72850655-2353-4DD7-A23D-ADCD46003287 Q28069259-F0D595B3-85D5-43CE-812B-44F11CCCEC68 Q33337970-E6436755-A76C-40A3-92BD-95F713202E07 Q33389519-CBD8C747-CED2-4EED-89D3-3B54D519BC16 Q33393811-5B5D4827-C84B-438A-B778-4CBB3B65F88C Q33433129-A75090C6-C898-4D58-AEEA-622467E4945F Q33711241-EED79B07-150A-433F-AEE8-2AB5B5C86716 Q33755032-B19991FB-7D4B-462E-856C-A76F30D6B335 Q33779701-D733C838-AC95-48C5-9158-CA4B1A009F69 Q33828971-9793FBA1-69E7-46C6-916F-C55B23008037 Q34617795-036B8FE1-C634-4D20-ABA1-C8D5CA7AEF97 Q34650974-62570FFD-27E6-4989-B55B-ECB9778F07C5 Q34989110-94A3414D-2578-45CF-8356-BEC74BB402F7 Q36536982-AAD314C8-3D38-41DC-8CAE-4FDCBE166BED Q36614394-8C7F8F84-126F-4D4F-A409-D08DB77124D0 Q36614602-613CAA36-4ED9-4124-8FD9-65E6E485AC73 Q36720792-FD05178C-B6C3-4B1D-B433-49B80CF8A7DD Q37042575-4723F219-381C-400E-9CFF-202F62D352DB Q37081094-72F8F944-0240-493F-98CC-96C12AB3EF78 Q37183479-91686559-7001-424A-BA9F-D60B0581524D Q37357165-E1C063FC-7BA9-496A-A36D-8E8B8088E42B Q37403462-5E88822C-3A4A-4C51-82CD-3F8DD403F7E8 Q37447932-3E440E48-7BCB-4E54-9E80-EA2E9939474B Q37467770-661A53D6-8B4A-4E02-9D98-6B0E6D2E979C Q37477979-F5FA2784-708F-4E20-A93B-E62DC4E8C03B Q37580222-5427E6DC-F345-477F-9A79-A01EC9D48585 Q38436106-DC176AA1-D45E-471A-BA87-79010C76DAC5 Q38633055-49C3C2F9-9952-44C4-B578-716EBC27CC04 Q38740840-76DAA3C9-D225-4DCA-891B-487696C5A10D Q38827826-C4076914-439C-465C-8642-D94566E9A29C Q39199269-7E3F5F7F-F47D-497D-8FCF-330DAC25262F Q40265325-0377B014-8031-4A42-866A-B0A5E4844C69 Q41971011-0610A7CC-ACA8-4930-AA92-3246BF1C3851 Q42129757-E855E72C-8A35-4848-AFE2-ABACC5409944 Q42170790-DB368CC2-F710-41F5-B7AB-640416208A51 Q43936243-E69B5FE0-BE33-498B-9B43-32C4E1DBA212

P2860

Palliative chemotherapy for advanced gastric cancer.

http://www.wikidata.org/entity/Q35936039

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Palliative chemotherapy for advanced gastric cancer.

@ast

Palliative chemotherapy for advanced gastric cancer.

@en

type

label

Palliative chemotherapy for advanced gastric cancer.

@ast

Palliative chemotherapy for advanced gastric cancer.

@en

prefLabel

Palliative chemotherapy for advanced gastric cancer.

@ast

Palliative chemotherapy for advanced gastric cancer.

@en

P1433

Q35936039-331BCC59-AA0A-4C28-833D-8845AE005440

P1476

Q35936039-1FE548C2-1AD7-4B33-AA65-83BC38632094

P2093

Q35936039-3E2451C3-ACB0-44C3-88E2-817998CBBD76

Q35936039-71C1E793-A965-4C96-8B1B-DCDC10B75E18

Q35936039-7DA13590-B52F-4B62-B5C9-E4CC4EEEC67D

P2860

Q35936039-0AB13206-5AAA-42D4-A363-00B0E32B20CF

Q35936039-0C5B998A-A962-4FCD-BA64-016D75279ACA

Q35936039-0F1CF60C-A645-4F9E-872D-4C69740B60D0

Q35936039-164B4926-B093-4F56-B26B-E6BFFF98EEC3

Q35936039-19E0D8FF-7ADA-476C-8838-73490598F23F

Q35936039-1F7F3137-249B-42C2-9BB7-2A7B63972B52

Q35936039-36FCC382-3771-40DD-A5E1-15B37953F9DB

Q35936039-38A62314-3780-42D1-B8FB-9D29C2A803E7

Q35936039-3D2780F1-781B-498E-8900-CB36445C4817

Q35936039-3DCA40A4-C67B-4235-BCE7-C691211B1582

P304

Q35936039-739D9558-BF12-4A38-B856-B7365F0D0873

P31

Q35936039-C30F7EF7-0ECE-4435-A0C8-489A24FA6EFB

Q35936039-b6b9e5cf-b76e-4814-82e0-955af562b948

P356

Q35936039-0E8F5073-8E6A-4B0F-8A30-8AB5D7120372

P433

Q35936039-F516044F-E093-4237-B424-80883F60C193

P478

Q35936039-527E10FB-8A8B-41D8-9F1D-785473A83E7E

P577

Q35936039-A5EF3A74-02F9-4053-9396-6206E5F00269

P5875

Q35936039-C45742FA-8D37-4AAD-A643-88CD5BCABB62

P698

Q35936039-0B82AD66-402C-418A-900C-2162CD5C988D

P921

Q35936039-E208C18D-F723-443E-87F6-E561B0437AD3

P356

P1433

Annals of Oncology

P1476

Palliative chemotherapy for advanced gastric cancer.

@en

P2093

M Hejna

http://www.w3.org/2001/XMLSchema#string

M Raderer

http://www.w3.org/2001/XMLSchema#string

S S Wöhrer

http://www.w3.org/2001/XMLSchema#string

P2860

Reporting results of cancer treatment

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial.

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.

Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.

P304

1585-1595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDH422

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8200550

http://www.w3.org/2001/XMLSchema#string

P698

15520058

http://www.w3.org/2001/XMLSchema#string

P921